Evidence map›Paper›PMID 41184109›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025

[Effects of nebulized self

Meizhi Li, Fei Peng, Quan Zhang, Yanna Wu, Jingping Sun, Si Lei, Shangjie Wu

Abstract readEnglish Abstract
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meizhi LiDepartment of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha 410011.
Fei PengDepartment of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha 410011.
Quan ZhangDepartment of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha 410011.
Yanna WuDepartment of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha 410011.
Jingping SunDepartment of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha 410011.
Si LeiHunan Provincial Evidence-based Medicine Center, Changsha 410011. leisi0831@csu.edu.cn.
Shangjie WuDepartment of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha 410011. wushangjie@csu.edu.cn.

Funding

the Hunan Provincial Traditional Chinese Medicine Research Project D2022017the Science and Technology Achievements Conversion Project of Qinghai Province 2017-SF-122
6 · The paper itself

Abstract

objectivesChronic obstructive pulmonary disease (COPD) is a major chronic respiratory condition with high morbidity and mortality, imposing a serious economic and public health burden. The World Health Organization ranks COPD among the top 4 chronic diseases worldwide. Zangsiwei Qingfei Mixture (ZSWQF), a novel Tibetan herbal formulation independently developed by our research team, has shown therapeutic potential for chronic respiratory diseases. This study aims to evaluate the effects of aerosolized ZSWQF on cigarette smoke-induced COPD in mice and explore its underlying mechanisms.

methodsThirty C57 mice were randomly divided into a Control group, a COPD group, and a ZSWQF group. The Control group received saline aerosol inhalation without cigarette smoke exposure; both the COPD group and the ZSWQF group were exposed to cigarette smoke, with the former receiving saline inhalation and the latter treated with ZSWQF aerosol. White blood cell (WBC) count was performed using a fully automatic blood cell analyzer. Serum, alanine transaminase (ALT), and serum creatinine (SCr), as well as interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF)-α levels in serum and bronchoalveolar lavage fluid (BALF) were measured by enzyme-linked immunosorbent assay (ELISA). BALF cell classification was determined using a hematology analyzer. Lung function was assessed with a small animal pulmonary function system, including airway resistance (RI) and cyclic dynamic compliance (CyDN). Lung tissues were stained with hematoxylin and eosin (HE), and mean linear intercept (MLI) and destruction index (DI) were calculated to evaluate morphological changes. Network pharmacology was applied to identify disease-related and ZSWQF-related targets, followed by intersection and protein-protein interaction (PPI) network analysis, and enrichment analysis of biological functions and pathways. Primary type II alveolar epithelial cell (AEC II) from SD rats were isolated and divided into a Control group, a lipopolysaccharide (LPS) group, a normal serum group, a water extract of ZSWQF (W-ZSWQF) group, a ZSWQF containing serum group, and a MLN-4760 [angiotensin-converting enzyme (ACE) 2 inhibitor]. Western blotting was performed to assess protein expression of ACE, p38 [a mitogen-activated protein kinase (MAPK)], phospho (p)-p38, extracellular signal-regulated kinases 1 and 2 (ERK1/2), p-ERK1/2, c-Jun N-terminal kinase (JNK), p-JNK, inhibitor of nuclear factor-kappa B alpha (IκBα), p-IκBα, and p-p65 subunit of nuclear factor-kappa B (NF-κBp65).

resultsWBC counts were significantly higher in the COPD group than in controls (

conclusionsAerosolized ZSWQF provides protective effects in COPD mice by reducing airway inflammation and remodeling.

Indexed as

Drugs, Chinese HerbalPulmonary Disease, Chronic ObstructiveAdministration, InhalationAnimalsBronchoalveolar Lavage FluidInflammationInterleukin-6LungMaleMiceMice, Inbred C57BLNetwork PharmacologySmokeTumor Necrosis Factor-alphaDrugs, Chinese HerbalInterleukin-6SmokeTumor Necrosis Factor-alphaaerosol inhalationanti-inflammatorychronic obstructive pulmonary diseaseinterleukin-6network pharmacologyZangsiwei Qingfei Mixture

Identifiers

PMID41184109
PMCPMC12554867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.